Sanuwave Announces Q3 FY2026 Financial Results
Globe Newswire•10/11/2026•17:00 ET
0
Key Highlights
- ➤Q3 revenue $8.6 million, down 24% from $11.3 million year over year
- ➤40 Ultramist systems sold, down from 155 in Q3 2025
- ➤Ultramist applicator revenue $6.9 million, up 2% year over year
- ➤GAAP operating loss $1.1 million versus $0.9 million operating income
- ➤Cash $6.6 million after approximately $2.3 million in sales-tax payments
Expert Statements
Morgan Frank, CEO of Sanuwave Health
“Q3 was very much the story of the CMS proposed rule”
Morgan Frank, CEO of Sanuwave Health
“This affected Sanuwave in multiple ways.”
Morgan Frank, CEO of Sanuwave Health
“The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”
Morgan Frank, CEO of Sanuwave Health
“This affected a number of our customers.”
Morgan Frank, CEO of Sanuwave Health
“The proposed changes to the 97610 code caused our market to take a sort of ‘wait and see’ approach across the quarter which, in combination with an ongoing market for used Ultramist® units had a significant effect on system sales in the quarter.”
Morgan Frank, CEO of Sanuwave Health
“The silver linings in all this were a 14% increase in HOPD (hospital outpatient department) rates for 97610 and a removal of Q1 status from the code which will allow it to be billed at the same time as other procedures rather than being packaged to zero.”
Morgan Frank, CEO of Sanuwave Health
“CMS and the American Medical Association RUC (the group who makes recommendations to CMS on the value of medical procedures) have also both signaled interest in looking at the structure of the 97610 code around issues like the scaling factors for multiple, large, or difficult wounds that are common in other wound care codes.”
Morgan Frank, CEO of Sanuwave Health
“We will seek to encourage and engage with this.”
Morgan Frank, CEO of Sanuwave Health
“Meanwhile, the company continues to gain traction in hospitals and other users in which cost savings by halting wound progression is the primary concern and continues to see this as a core opportunity going forward.”
Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025.
GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 million in Q3 2025.
Get started
Create a free account to read the full story.